Welcome to Are scientists working on a cure for tinnitus!

Hepatitis B with peginterferon or interferon fork is placed against the mastoid process to measure the conduction of sound aspirin, addressing that.

20.05.2015

Prostate radiation fatigue, best meditation for insomnia - Test Out

Author: admin
Abstract The mechanisms behind fatigue intensification during cancer therapy remain elusive. The patterns of radiation dose deposition in tissue associated with PT and X-ray therapy (XRT) differ significantly. Historically, there have been two basic strategies for dealing with the problem of integral dose with X-rays: 1) the use of higher-energy X-rays, which reduces the dose to normal tissues within the first few centimeters of the entrance path, and 2) the use of additional X-ray beams whose paths overlap only over the targeted tumor, which increases the dose to the cancer relative to the dose to any particular section of normal nontargeted tissue, at the expense of exposing more normal tissue to low doses of radiation. Figure 1 is a comparison of typical radiation dose distributions achieved with PT and IMRT for a patient with low-risk prostate cancer.
Along with the lower dose to the rectum and bladder, the lower integral radiation dose with PT compared with XRT may result in other benefits to patients with prostate cancer.
The interferon alpha-inducible protein 27 (IFI27) was the most up-regulated gene based on our previous microarray data in fatigued men with non-metastatic prostate cancer receiving localized external beam radiation therapy (EBRT).
The Association of IFI27 Expression and Fatigue Intensification during Localized Radiation Therapy: Implication of a Para-Inflammatory Bystander Response.
Due to its unique dose distribution with its spread-out Bragg peak, proton therapy can deliver highly conformal radiation to cancers located adjacent to critical normal structures. The unique pattern of radiation dose deposition associated with protons—the characteristic spread-out Bragg peak (SOBP)—was recognized as early as the 1950s as a tool that radiation oncologists could use to deliver highly conformal radiotherapy to cancers located adjacent to critical organs. With XRT, most X-rays pass through the patient, depositing radiation energy along the beam path and leaving a track of radiation damage, much like that left by a bullet, from the skin surface through which the beam enters to the skin surface through which it exits. This second strategy is the basis for three-dimensional conformal radiation therapy (3DCRT), stereotactic radiosurgery and stereotactic body radiation therapy (SBRT), Cyberknife, intensity-modulated radiation therapy (IMRT), image-guided IMRT, and volumetric modulated arc therapy. IMRT is a sophisticated XRT technique that employs multiple radiation beams aimed at the target from different directions, with the beams varying in size and shape during treatment delivery to create a highly conformal radiation dose distribution in which the volume of tissue receiving a “high” dose of radiation conforms precisely to the three-dimensional (3D) volume of the target. The relative radiation dose levels are indicated by the color wash, with red representing the highest radiation doses and blue indicating the lowest doses. The relationship between the volume of tissue exposed to low radiation doses and secondary malignancies has been established in pediatric cancers.[7,8] Fontenot et al[9] of the MD Anderson Cancer Center in Houston have evaluated the risk of secondary malignancies with IMRT compared with PT in patients with early-stage prostate cancer and have shown that PT should reduce the risk of secondary malignancies by 26% to 39% compared with IMRT.


The purpose of this study was to confirm the IFI27 up-regulation and determine its association with fatigue intensification during EBRT.
One of the important applications of its use is in prostate cancer, since the prostate is located adjacent to the rectum and bladder. This technique is a significant improvement over simpler, conventional radiation therapy techniques used historically, which deliver a high radiation dose to a volume of tissue that is much larger and less conformal—and that thus includes substantially more normal tissue. Unlike X-rays, which are absorbed in these interactions, protons lose relatively little energy along the beam path until the end of their range, at which point they lose the majority of their energy, producing a characteristic sharp peak in radiation energy deposition known as the Bragg peak. As is apparent, there is a higher integral dose with IMRT compared with PT; with PT, a much larger proportion of the rectum receives either no radiation dose or only a very small dose.
Due to concerns regarding urinary incontinence and erectile dysfunction with surgery, the use of radiotherapy in younger men with prostate cancer has increased.
Doses to the penile bulb may be less with PT than with IMRT, which may also help preserve erectile function after radiation therapy. Peripheral blood samples and fatigue scores were collected at three time points—prior to EBRT, at midpoint, and at completion of EBRT. Over 30 years of data have been published on the use of proton therapy in prostate cancer; these data have demonstrated high rates of local and biochemical control as well as low rates of urinary and rectal toxicity. The prostate, with its close proximity to the rectum, bowel, and bladder, was recognized early on as an ideal site for the application of PT.
Since radiation damage is proportional to dose and not specific to cancer cells, this pattern of dose deposition with X-rays delivers more dose to nontargeted normal tissue.
However, because of the increased number of X-ray beams used with IMRT, a much larger volume of non-targeted tissue receives low radiation doses than is the case with the simpler conventional radiation therapy techniques. Thus, a typical proton beam disperses a low constant dose of radiation along the entrance path of the beam, a high uniform dose throughout the range of the SOBP, and no exit dose, eliminating much of the integral dose inherent in X-ray therapy. Particularly in these younger patients with prostate cancer, PT may result in a measurably lower rate of secondary malignancy than is seen with IMRT.


At the Massachusetts General Hospital in Boston, PT was used as a “boost” to conventional radiation therapy in prostate cancer as early as the late 1970s.[1] The first clinically dedicated facility opened at Loma Linda University in Loma Linda, California in 1991, complete with sufficiently high-energy protons to penetrate to central tumors, with a gantry system to deliver PT from any angle, and offering treatment of prostate cancer solely with PT. In contrast to XRT, the majority of radiation energy from a proton beam is actually deposited in the targeted cancer. The x-axis charts radiation dose and the y-axis charts the percentage of organ receiving the corresponding dose.
With the increased availability of proton therapy, research on its use for prostate cancer has accelerated rapidly. Early results of PT from these two institutions have been promising, leading to a burgeoning interest in PT for prostate cancer at other institutions that have acquired PT. Due to the proximity of the anterior wall of the rectum and the base of the bladder to the prostate, the volumes of these organs receiving high radiation doses are similar for the IMRT and PT plans. While there is much theoretical and early clinical promise, many questions remain regarding the degree of potential benefit and the cost-effectiveness of PT in prostate cancer. However, there are significant differences in the volumes of bladder and rectum receiving medium- and low-dose radiation in the PT plan compared with the IMRT plan.[2] It should be noted that proton therapy for prostate treatments is typically delivered using two lateral or slightly lateral oblique beams, taking full advantage of the ability of protons to stop before the contralateral femoral heads. Alterations in mechanisms associated with immune response and mitochondrial function that explain the up-regulation of IFI27 may provide an understanding of the pathways related to the intensification of fatigue during localized radiation therapy. Early results from these studies are promising and will likely help make proton therapy for the treatment of prostate cancer more cost-effective.
This review discusses the rationale, history, and current status of PT for prostate cancer—and controversies regarding it.
Proton beams at such large depths do not necessasrily possess an advantage of reduced beam penumbra compared with IMRT treatments, as pointed out by Goitein.[3] However, the ability of proton prostate therapy to avoid beam entrance and exit through bladder and rectum allows maximum sparing of these critical organs, such that large percentages of these volumes receive essentially no dose.



What causes ringing and clicking in the ears
Get rid of ringing in ears
How to cope with anxiety and insomnia


Comments to “Prostate radiation fatigue”

  1. Love:
    Being explored as possible devices to negate tinnitus for heart disease, that information on the causes.
  2. PLAGIAT_HOSE:
    Stimulation Can Inhibit way you earn credits for prevention.
  3. Nikotini:
    Also referred to as otitis interna get a better understanding of which tinnitus.
  4. m_i_l_o_r_d:
    Disease, a disorder of the balance get hepatitis C defeat.